RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS

      폐경후 여성에서 경구용 에스트로젠 및 경피적 에스트론젠을 이용한 호르몬보충요법이 혈중 지질대사에 미치는 영향 = Long-Term Effects of Hormone Replacement Therapy with Oral or Percutaneous Estrogen on Serum Lipoprotein Levels in Postmenopausal Women

      한글로보기

      https://www.riss.kr/link?id=A3359528

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Estrogen replacement therapy is known to reduce the incidence of cardiovascular disease in postmenopausal women, and its beneficial effect is thought to be mediated in part by the favorable changes in serum lipoprotein levels. However, the long-term effects on serum lipoprotein levels of setrogens in low doses currently used have not been precisely evaluated in Korean postmenopausal women. We conducted the randomized 1-year trials of estrogens in postmenopausal women to evaluate the long-term effects of oral estrogen (Premarin at the dose of 0.625 mg per day, 32 patients) and transdermal estrogen (Estraderm TTS at the dose of 50 micro g per day, 30 patients) on serum lipoprotein levels. Serum total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol levels in fasting state were measured in all subjects at baseline and every 3 month during treatment for 12 months. The values during treatment levels were compared with that of baseline levels. The conjugated estrogen (Premarin) and trasdermal estrogen increased the serm HDL cholesterol levels throughout the study period. The increase of HDL cholesterol in the Estraderm group was somewhat less than that in the Premarin group at 3 months of treatment, but the thereafter no difference was observed between two groups. Serum LDL cholesterol levels did not change significantly in both groups. And serum total cholesterol levels also did not change significantly in both groups except at 12 months of treatment in the Premarine group. Significant increases in serum triglyceride levels were noted in the Premarin group from 6 months of treatment, but not in the Estraderm group. These data suggest that estrogens in low doses, administered by either oral or percutaneous route, maintain the long-term favorable effects on serum lipoprotein levels in postmenopausal women.
      번역하기

      Estrogen replacement therapy is known to reduce the incidence of cardiovascular disease in postmenopausal women, and its beneficial effect is thought to be mediated in part by the favorable changes in serum lipoprotein levels. However, the long-term e...

      Estrogen replacement therapy is known to reduce the incidence of cardiovascular disease in postmenopausal women, and its beneficial effect is thought to be mediated in part by the favorable changes in serum lipoprotein levels. However, the long-term effects on serum lipoprotein levels of setrogens in low doses currently used have not been precisely evaluated in Korean postmenopausal women. We conducted the randomized 1-year trials of estrogens in postmenopausal women to evaluate the long-term effects of oral estrogen (Premarin at the dose of 0.625 mg per day, 32 patients) and transdermal estrogen (Estraderm TTS at the dose of 50 micro g per day, 30 patients) on serum lipoprotein levels. Serum total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol levels in fasting state were measured in all subjects at baseline and every 3 month during treatment for 12 months. The values during treatment levels were compared with that of baseline levels. The conjugated estrogen (Premarin) and trasdermal estrogen increased the serm HDL cholesterol levels throughout the study period. The increase of HDL cholesterol in the Estraderm group was somewhat less than that in the Premarin group at 3 months of treatment, but the thereafter no difference was observed between two groups. Serum LDL cholesterol levels did not change significantly in both groups. And serum total cholesterol levels also did not change significantly in both groups except at 12 months of treatment in the Premarine group. Significant increases in serum triglyceride levels were noted in the Premarin group from 6 months of treatment, but not in the Estraderm group. These data suggest that estrogens in low doses, administered by either oral or percutaneous route, maintain the long-term favorable effects on serum lipoprotein levels in postmenopausal women.

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼